Kwang Dong Pharmaceutical Co (009290) Fair Value & Analysis
Consumer Defensive · KR · Market cap 318B KRW
Fair value as of: Jun 24, 2026
Analysis
Kwang Dong Pharmaceutical Co (009290) currently trades at 5,340 KRW, while our model-based Fair Value estimate is 9,289 KRW — implying the stock looks roughly 74.0% undervalued today. We read business quality at 89/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti-inflammatory agents, neuropsychiatric solvent, digestive organ agent, antibiotic, and vitamins. The company also offers supplements for low content vitamin, mineral or vital energy substance and quasi drugs. In addition, it provides blackberry, ginger lonicerae flos, vita gold, and red ginseng gold drinks, as well as offers water, mixed drinks, tea drinks, and other drinks; and traditional health foods. The company offers its products through operation of TV, radio, and print advertising. Kwang Dong Pharmaceutical Co., Ltd. was founded in 1963 and is based in Seoul, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Kwang Dong Pharmaceutical Co (009290) undervalued?
What is the fair value of 009290?
What is the quality score of 009290?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.